NCT06927102 From Exclusion to Inclusion: Analysing Follow-up Discontinuity in Breast Cancer
| NCT ID | NCT06927102 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Basavatarakam Indo American Cancer Hospital & Research Institute |
| Condition | Breast Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2025-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-05-01 with a primary completion date of 2025-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to determine the proportion of patients who are lost-to-follow-up at five years, identify factors associated with loss of follow-up , and explore patient-reported barriers to follow-up in a public sector cancer care setting. The main question it aims to answer is : Do proactive outreach programs help in improving follow-up rates among breast cancer patients who are categorized as "lost-to-follow-up." This study will be conducted in a real-world cohort of women with non-metastatic breast cancer treated at a tertiary care centre, between 2017-2018.
Eligibility Criteria
Inclusion Criteria: 1. Patients newly diagnosed with non-metastatic breast cancer between 2017-2018 2. Patients categorized as "lost-to-follow-up", as defined above 3. Patients willing to participate upon re-engagement Exclusion Criteria: 1. Patients with incomplete medical records 2. Patients who have taken part of the treatment at another hospital/centre 3. Patients who have relocated permanently out of the study region Withdrawal Criteria: 1\. Patient withdraws consent
Contact & Investigator
Nisha Hariharan, MS,HBNI Fellow Breast Oncology
PRINCIPAL INVESTIGATOR
Basavatarakam Indo American Cancer Hospital & Research Institute
Frequently Asked Questions
Who can join the NCT06927102 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06927102 currently recruiting?
Yes, NCT06927102 is actively recruiting participants. Contact the research team at research.oncology@basavatarakam.org for enrollment information.
Where is the NCT06927102 trial being conducted?
This trial is being conducted at Hyderabad, India.
Who is sponsoring the NCT06927102 clinical trial?
NCT06927102 is sponsored by Basavatarakam Indo American Cancer Hospital & Research Institute. The principal investigator is Nisha Hariharan, MS,HBNI Fellow Breast Oncology at Basavatarakam Indo American Cancer Hospital & Research Institute. The trial plans to enroll 1,500 participants.